ClinicalTrials.gg

Program

JAR-2203

A development code.

Its studies are mostly in Hyperlipoproteinemias, led by Beijing Jiake Ruikang Pharmaceutical Technology.

Furthest: phase 1, since Nov 8, 20261 company-led study, 1 open or runningNext primary completion: Jul 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Jiake Ruikang Pharmaceutical Technology11 open or runningphase 1since Nov 8, 2026Nov 8, 2026Jul 30, 2027phase 1 · NCT07937254

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 8, 2026First study: phase 1 study in Lipid Metabolism DisordersFirst studyNCT07937254 · 44 planned · China

Ahead

  1. Jul 30, 2027Primary completion: phase 1 study in Lipid Metabolism DisordersNCT07937254

TargetBeta

LPA →read by rule
“JAR-2203 is an investigational small interfering RNA (siRNA) targeting LPA mRNA to reduce plasma lipoprotein(a) \[Lp(a)\] levels.”study text, by rule · the study

Other programs on LPA

ProgramCompanyFurthest phaseStudies
HRS-5346Jiangsu HengRui Medicinephase 26
DII235Novartisphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07937254Lipid Metabolism Disorders · China1RecruitingJul 30, 202744

How it is read

Names in the registry

  • “JAR-2203”, 1 entry

Codes read as this program: JAR2203.

Conditions, from the studies’ own filings

First seen by our ledger Nov 17, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.